Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Current guidelines for follow-up of high-risk adenomas may not apply to all patients

05 Oct 2019

A recent study suggests that the 2012 Multi-Society Task Force recommendation for the surveillance of high-risk adenoma (HRA) may not be applicable to all patients.

Patients who were followed at a median of 4.5 years did not appear to have more HRA than those who were followed at 3 years (25.2 percent vs 21.0 percent; p=0.062). Baseline characteristics were comparable between the two groups.

The following factors were predictors of future HRAs: older age, male gender, having a history of polyps and piecemeal resection of an HRA. The removal of ≥3 adenomas in 2008 as well as a combination of multiple, large and advanced polyps were associated with a higher risk of future HRAs.

“We showed that a combination of patient demographics, procedural factors and pathology best determines the surveillance colonoscopy interval,” the authors said.

This study sought to determine whether variation from the 3-year follow-up interval correlated with subsequent HRA. A total of 495 patients who had their HRA removed during a 2008 colonoscopy were analysed in 2016. The frequency of finding another HRA at follow-up intervals were then compared.

The current guidelines were used as the referent group. Logistical regression was performed to determine whether any patient characteristics, procedural factors or HRA type predicted the development of HRAs on follow-up colonoscopy.

HRAs included an adenoma measuring ≥10 mm, ≥3 adenomas found during a single procedure, and an adenoma with high-grade dysplasia or villous architecture. The current Multi-Society Task Force guideline for timing of surveillance colonoscopy after removal of an HRA is 3 years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.